23-01-2013

The extended offer period for BASF’s voluntary cash offer to shareholders of Pronova BioPharma ASA (Pron) ended on January 18, 2013, 16:30 CET. During the offer period, a total of 293,975,655 Pronova shares have been tendered to BASF. This corresponds to 97.7% of all Pronova shares. Based on ...

more

14-12-2012

Clavis Pharma ASA announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed. The results found that ...

more

11-12-2012

Clavis Pharma ASA announced that is has reached the enrolment target for its Phase III CLAVELA study investigating elacytarabine in patients with relapsed or refractory acute myeloid leukaemia (AML). Elacytarabine is a novel, patented lipid-conjugated form of the anti-cancer drug cytarabine, ...

more

19-11-2012

Clavis Pharma ASA announced results of the LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of CP-4126 (also known as CO-101), versus gemcitabine in metastatic pancreatic cancer. The trial, which was conducted by partner Clovis Oncology, Inc., showed that there was no difference in ...

more

17-08-2012

Algeta ASA announced it has initiated a new research and development program aimed at investigating the effect of a novel Targeted Thorium Conjugate (TTC) on hematological cancers.The program will focus on the development of an undisclosed monoclonal antibody, which is highly selective for a ...

more

09-07-2012

Photocure ASA announced the appointment of Erik Dahl to its management team as the Chief Financial Officer, effective 15 August 2012.Dahl joins Photocure with more than 20 years of experience in senior level financial management roles in both international public and private companies. He has ...

more

12-06-2012

Photocure ASA announced the results of the phase 2b study in acne with Visonac (methyl aminolevulinate 80mg/g), a topical acne treatment. In this study, Visonac showed a statistically significant reduction in inflammatory lesions and overall improvement in acne severity.The phase 2b trial ...

more

Overall survival in Alpharadin arm significantly increased by 44%

05-06-2012

Algeta ASA announced that updated data from the pivotal phase III ALSYMPCA trial for its investigational drug Alpharadin (radium-223 dichloride) confirm the improvement in overall survival of Alpharadin in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, ...

more

The EU grant is for development of a prophylactic treatment to prevent severe bleeding and death in newborns caused by Fetal/Neonatal Alloimmune Trombocytopenia

09-05-2012

Prophylix Pharma AS announced that its project proposal for developing a new therapy to prevent Fetal/Neonatal Alloimmune Trombocytopenia (FNAIT) has been favorably evaluated by the EU Commission and will receive up to €6 million in funding under the Seventh Framework Programme (FP7-HEALTH). ...

more

03-05-2012

Algeta ASA announced that its research collaboration with Sanofi (previously Genzyme) has been extended. This collaboration, which was announced in April 2011, is focused on evaluating the potential of linking the alpha-emitter thorium-227 to a proprietary antibody from Genzyme to create a ...

more